Cabaletta Bio is focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Successful clinical trials in patients are required to gain regulatory approval for new medications to advance patient care and may be required to support any approved products. Information about Cabaletta Bio clinical trials is listed below.
DesCAARTes™ Clinical Trial+
A Phase 1 Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Mucosal Pemphigus Vulgaris, Sponsored by Cabaletta Bio, Inc.
Mucosal pemphigus vulgaris is an autoimmune disorder in which painful blisters are formed on the inside of the mouth, nose, throat, eyelids, anus, and genitals. In an autoimmune disorder, your body’s own defense system (the immune system) attacks the body by mistake. In mucosal pemphigus vulgaris, a subset of B cells – a type of immune cell in your body – mistakenly attack a protein related to skin cells, called desmoglein 3 (DSG3). B cells are important for fighting infections, but “bad” B cells make antibodies that attack DSG3. This causes formation of painful blisters.
Current treatments for pemphigus vulgaris most often include corticosteroids and immunosuppressants, which non-specifically suppress the immune system, leading to responses that are often transient or incomplete, with a risk of fatal infections and other side effects.FIND OUT MORE